Variabilite genetique des virus des hepatites B & C : implications pour le diagnostic

Available from INIST (FR), Document Supply Service, under shelf-number : AR 16195 / INIST-CNRS - Institut de l'Information Scientifique et TechniqueSIGLEMinistere de l'Enseignement Superieur et de la Recherche, 75 - Paris (France)FRFranc

Mise au point d'un modele pharmacologique pour la recherche de produits antipaludeens perturbant le metabolisme phospholipidique du parasite

Available at INIST (FR), Document Supply Service, under shelf-number : AR 15141 / INIST-CNRS - Institut de l'Information Scientifique et TechniqueSIGLEFRFranc

Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia.

AbstractBackgroundThe most advanced dengue vaccine candidate is a live-attenuated recombinant vaccine containing the four dengue viruses on the yellow fever vaccine backbone (CYD-TDV) developed by Sanofi Pasteur. Several analyses have been published on the safety and immunogenicity of the CYD-TDV vaccine from single trials but none modelled the heterogeneity observed in the antibody responses elicited by the vaccine.MethodsWe analyse the immunogenicity data collected in five phase-2 trials of the CYD-TDV vaccine. We provide a descriptive analysis of the aggregated datasets and fit the observed post-vaccination PRNT50 titres against the four dengue (DENV) serotypes using multivariate regression models.ResultsWe find that the responses to CYD-TDV are principally predicted by the baseline immunological status against DENV, but the trial is also a significant predictor. We find that the CYD-TDV vaccine generates similar titres against all serotypes following the third dose, though DENV4 is immunodominant after the first dose.ConclusionsThis study contributes to a better understanding of the immunological responses elicited by CYD-TDV. The recent availability of phase-3 data is a unique opportunity to further investigate the immunogenicity and efficacy of the CYD-TDV vaccine, especially in subjects with different levels of pre-existing immunity against DENV.Modelling multiple immunological outcomes with a single multivariate model offers advantages over traditional approaches, capturing correlations between response variables, and the statistical method adopted in this study can be applied to a variety of infections with interacting strains